Mridula George, MD | Rutgers Cancer ...

Dr. Mridula George, MD

Claim this profile

Rutgers Cancer Institute of New Jersey

Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
38 drugs studied

Area of expertise

1

Breast Cancer

Global Leader

Mridula George, MD has run 14 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Breast Cancer

Mridula George, MD has run 4 trials for Breast cancer. Some of their research focus areas include:

Stage IV
HER2 negative
Stage III

Affiliated Hospitals

Image of trial facility.

Rutgers Cancer Institute Of New Jersey

Image of trial facility.

Monmouth Medical Center - Southern Campus

Clinical Trials Mridula George, MD is currently running

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Elacestrant Combinations

for Breast Cancer

This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.

Recruiting

1 award

Phase 1 & 2

More about Mridula George, MD

Clinical Trial Related

2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Mridula George, MD has experience with

  • Letrozole
  • Pelareorep
  • Paclitaxel
  • Placebo
  • Tucatinib
  • Neoadjuvant Chemotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Mridula George, MD specialize in?

Is Mridula George, MD currently recruiting for clinical trials?

Are there any treatments that Mridula George, MD has studied deeply?

What is the best way to schedule an appointment with Mridula George, MD?

What is the office address of Mridula George, MD?

Is there any support for travel costs?